<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839003</url>
  </required_header>
  <id_info>
    <org_study_id>AC-018-IT</org_study_id>
    <nct_id>NCT04839003</nct_id>
  </id_info>
  <brief_title>A Registry of AL Amyloidosis (ReAL)</brief_title>
  <acronym>ReAL</acronym>
  <official_title>A Registry to Investigate Real-world Natural History, Impact of Therapies and Patterns of Progression of AL Amyloidosis (ReAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thanks to this registry, it will be possible to collect data at diagnosis and during follow&#xD;
      up, in order to be able to describe the natural history of AL amyloidosis in a real-world&#xD;
      setting and to define and validate prognostic models, response and relapse criteria&#xD;
      applicable at any point of the disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Creation of a registry of patients with AL amyloidosis</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>AL Amyloidosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      It will be generated a biobank of body fluids (serum, plasma, urine) and relevant cellular&#xD;
      (bone marrow and peripheral blood mononuclear cells) and tissue samples (bone marrow,&#xD;
      periumbilical fat, possibly other biopsied organs) from patients with AL amyloidosis. We will&#xD;
      obtain research samples from diagnostic leftovers of consenting patients at diagnosis and at&#xD;
      each subsequent visit.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be entered the database pending on expressing an informed consent of the use&#xD;
        of their data for research purposes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosis of systemic AL amyloidosis;&#xD;
&#xD;
          2. treatment-naïve (pre-treatment data collected at participating center available for&#xD;
             retrospective part);&#xD;
&#xD;
          3. age ≥18 years;&#xD;
&#xD;
          4. ability to understand and willingness to sign an informed consent (patients who&#xD;
             already sign informed consent for clinical data to be used in retrospective analyses&#xD;
             will be accepted);&#xD;
&#xD;
          5. planned (or ongoing) follow-up at participating center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. non-AL amyloidosis;&#xD;
&#xD;
          2. previous treatment for AL amyloidosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Palladini, MD</last_name>
      <phone>+390382502994</phone>
      <email>giovanni.palladini@unipv.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>GIOVANNI PALLADINI</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>amyloidosis</keyword>
  <keyword>prognosis</keyword>
  <keyword>registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

